DexCom Inc.

324.60-10.14-3.03%Vol 676.42K1Y Perf 0.45%
May 16th, 2022 16:00 DELAYED
BID312.20 ASK337.73
Open334.78 Previous Close334.74
Pre-Market- After-Market329.99
 - -  5.39 1.66%
Target Price
537.40 
Analyst Rating
Strong Buy 1.20
Potential %
65.56 
Finscreener Ranking
★★     44.71
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     40.08
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     63.10
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
6.16 
Earnings Rating
Neutral
Market Cap31.85B 
Earnings Date
28th Apr 2022
Alpha0.03 Standard Deviation0.16
Beta1.04 

Today's Price Range

323.09339.19

52W Range

302.61659.45

5 Year PE Ratio Range

-86.50418.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.86%
1 Month
-34.04%
3 Months
-16.18%
6 Months
-50.16%
1 Year
0.45%
3 Years
174.99%
5 Years
377.00%
10 Years
3 015.16%

TickerPriceChg.Chg.%
DXCM324.60-10.1400-3.03
AAPL145.54-1.5700-1.07
GOOG2 295.85-34.4600-1.48
MSFT261.500.38000.15
XOM90.952.09002.35
WFC42.21-0.4300-1.01
JNJ178.081.23000.70
FB200.041.42000.71
GE74.63-0.4200-0.56
JPM118.26-0.8300-0.70
Financial StrengthValueIndustryS&P 500US Markets
4.50
5.30
0.49
0.98
2.60
Leverage Ratio 2.20
ProfitabilityValueIndustryS&P 500US Markets
67.40
10.60
15.10
-0.50
8.26
RevenueValueIndustryS&P 500US Markets
2.57B
26.21
26.79
32.99
Earnings HistoryEstimateReportedSurprise %
Q01 20220.500.32-36.00
Q04 20210.860.68-20.93
Q03 20210.620.8943.55
Q02 20210.430.7676.74
Q01 20210.310.336.45
Q04 20200.910.910.00
Q03 20200.640.9446.88
Q02 20200.310.79154.84
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.71-4.05Negative
9/2022 QR0.993.13Positive
12/2022 FY3.28-2.38Negative
12/2023 FY4.61-0.43Negative
Next Report Date-
Estimated EPS Next Report0.50
Estimates Count11
EPS Growth Next 5 Years %17.40
Volume Overview
Volume676.42K
Shares Outstanding98.13K
Shares Float87.32M
Trades Count21.43K
Dollar Volume225.01M
Avg. Volume891.84K
Avg. Weekly Volume1.08M
Avg. Monthly Volume801.44K
Avg. Quarterly Volume794.93K

DexCom Inc. (NASDAQ: DXCM) stock closed at 324.6 per share at the end of the most recent trading day (a -3.03% change compared to the prior day closing price) with a volume of 676.42K shares and market capitalization of 31.85B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 6400 people. DexCom Inc. CEO is Kevin R. Sayer.

The one-year performance of DexCom Inc. stock is 0.45%, while year-to-date (YTD) performance is -39.55%. DXCM stock has a five-year performance of 377%. Its 52-week range is between 302.61 and 659.4518, which gives DXCM stock a 52-week price range ratio of 6.16%

DexCom Inc. currently has a PE ratio of 160.90, a price-to-book (PB) ratio of 15.00, a price-to-sale (PS) ratio of 12.38, a price to cashflow ratio of 69.40, a PEG ratio of 2.32, a ROA of 4.25%, a ROC of 6.34% and a ROE of 9.81%. The company’s profit margin is 8.26%, its EBITDA margin is 15.10%, and its revenue ttm is $2.57 Billion , which makes it $26.21 revenue per share.

Of the last four earnings reports from DexCom Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.50 for the next earnings report. DexCom Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for DexCom Inc. is Strong Buy (1.2), with a target price of $537.4, which is +65.56% compared to the current price. The earnings rating for DexCom Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

DexCom Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

DexCom Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.25, ATR14 : 22.62, CCI20 : -95.61, Chaikin Money Flow : -0.26, MACD : -39.13, Money Flow Index : 18.24, ROC : -21.45, RSI : 27.84, STOCH (14,3) : 17.06, STOCH RSI : 0.84, UO : 33.90, Williams %R : -82.94), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of DexCom Inc. in the last 12-months were: Andrew K. Balo (Sold 18 516 shares of value $9 303 509 ), Barbara E. Kahn (Sold 2 766 shares of value $1 219 757 ), Barry J. Regan (Sold 5 208 shares of value $2 991 322 ), Chad Patterson (Sold 4 858 shares of value $2 181 568 ), Donald Abbey (Sold 1 263 shares of value $683 747 ), Jake Leach (Sold 24 018 shares of value $9 671 973 ), Jay S. Skyler (Sold 20 000 shares of value $8 527 404 ), Jereme M. Sylvain (Sold 1 594 shares of value $851 045 ), Kevin R. Sayer (Sold 48 191 shares of value $23 402 717 ), Mark G. Foletta (Sold 960 shares of value $559 458 ), Matthew Vincent Dolan (Sold 2 186 shares of value $928 359 ), Nicholas Augustinos (Sold 3 306 shares of value $1 795 880 ), Patrick Michael Murphy (Sold 2 487 shares of value $1 238 087 ), Paul R. Flynn (Sold 2 004 shares of value $1 106 135 ), Quentin S. Blackford (Sold 18 562 shares of value $10 165 281 ), Richard A. Collins (Sold 1 500 shares of value $970 575 ), Sadie Stern (Sold 2 051 shares of value $1 278 335 ), Shelly Ramasamy Selvaraj (Sold 8 174 shares of value $4 137 968 ), Steven R. Pacelli (Sold 6 249 shares of value $3 055 772 ), Sumi Shrishrimal (Sold 807 shares of value $380 775 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
13 (86.67 %)
15 (88.24 %)
15 (88.24 %)
Moderate Buy
1 (6.67 %)
1 (5.88 %)
1 (5.88 %)
Hold
1 (6.67 %)
1 (5.88 %)
1 (5.88 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.20
Strong Buy
1.18
Strong Buy
1.18

DexCom Inc.

DexCom Inc designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

CEO: Kevin R. Sayer

Telephone: +1 858 200-0200

Address: 6340 Sequence Drive, San Diego 92121, CA, US

Number of employees: 6 400

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

57%43%

Bearish Bullish

61%39%

TipRanks News for DXCM

Sat, 30 Apr 2022 03:53 GMT Dexcom (DXCM) Gets a Buy Rating from Robert W. Baird

- TipRanks. All rights reserved.

Sat, 12 Feb 2022 04:20 GMT Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Illumina (ILMN)

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 15:24 GMT Dexcom (DXCM) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Mon, 10 Jan 2022 13:45 GMT Dexcom (DXCM) Gets a Hold Rating from BTIG

- TipRanks. All rights reserved.

News

Stocktwits